Photo: Depositphotos
Jun 17, 2025, 13:50
Penn Medicine – Abramson Cancer Center Shared ASCO25 Study on ctDNA Blood Test For Breast Cancer
Penn Medicine – Abramson Cancer Center hared a post on X:
“A study from ASCO25 looked at using a ctDNA blood test to identify early signs that Breast Cancer was becoming resistant to Tx before showing up on other tests. Angie Demichele, who served as the study discussant in the ASCO Plenary Session, weighed in.”
Read Full Article on ASCO Daily News.
Read also OncoDaily’s Special Article: “ASCO 2025 Plenary Highlights: Key Practice-Changing Data Across TOP 5 ATOMIC, MATTERHORN, SERENA-6, VERIFY, and NIVOPOSTOP Trials”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38